Brief: UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio
20/02/2025 13:29
Feb 20 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA: EXPANSION OF ONCOLOGY PIPELINE PORTFOLIO
THROUGH
ACQUISITION OF ASSETS RELATING TO ONCOLYTIC VIRUS ICVB-1042 FROM
ICONOVIR BIO
Source text: ID:nBw8njrmga
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors